Gliclazide and Aprepitant drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gliclazide (gliclazide) and Aprepitant (aprepitant). Common drug interactions include hyponatraemia among females and anaphylactic reaction among males.

The phase IV clinical study analyzes what interactions people have when they take Gliclazide and Aprepitant. It is created by eHealthMe based on reports of 28 people who take the same drugs from the FDA, and is updated regularly.

What is Gliclazide?

Gliclazide has active ingredients of gliclazide. It is often used in diabetes. eHealthMe is studying from 28,131 Gliclazide users. Check the latest studies of Gliclazide.

What is Aprepitant?

Aprepitant has active ingredients of aprepitant. eHealthMe is studying from 6,992 Aprepitant users. Check the latest studies of Aprepitant.

On Jul, 09, 2026

28 people who take Gliclazide and Aprepitant together, and have interactions are studied.

Gliclazide and Aprepitant drug interactions.

What are the common drug interactions of Gliclazide and Aprepitant, by gender? *:

female:

Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Nausea (feeling of having an urge to vomit)
Vomiting
Pneumonia
Arthralgia (joint pain)
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Abdominal pain lower
Alopecia (absence of hair from areas of the body)
Back pain
Chest pain

male:

Anaphylactic reaction (serious allergic reaction)
Cardiac arrest
Arteriosclerosis coronary artery (thickening and hardening of arteries- coronary artery)
Chills (felling of cold)
Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough)
Mesothelioma malignant (cancer that occurs in the thin layer of cells lining the body's internal organs, known as the mesothelium)
Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
Urinary tract infection
Vomiting
Asthenia (weakness)

What are the common drug interactions of Gliclazide and Aprepitant, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Hypertension (high blood pressure)

50-59:

n/a

60+:

Sepsis (a severe blood infection that can lead to organ failure and death)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Renal failure acute (rapid kidney dysfunction)
Cellulitis (infection under the skin)
Pneumonia
Renal failure (kidney dysfunction)
Arteriosclerosis coronary artery (thickening and hardening of arteries- coronary artery)
Arthralgia (joint pain)
Arthritis (form of joint disorder that involves inflammation of one or more joints)

What are the existing conditions these people have? *

High Blood Pressure: 7 people, 25.00%
Diarrhea: 6 people, 21.43%
Breast Cancer: 5 people, 17.86%
Pancreatic Carcinoma Metastatic (pancreatic cancer- metastatic): 4 people, 14.29%
Nausea And Vomiting: 4 people, 14.29%
Cervix Carcinoma (cancer of cervix): 3 people, 10.71%
Cervix Carcinoma Recurrent (repeated cancer of cervix): 3 people, 10.71%
Stomatitis (inflammation of mucous membrane of mouth): 3 people, 10.71%
Dyslipidaemia (abnormal amount of lipids): 3 people, 10.71%
Enteritis (inflammation of the small intestine): 3 people, 10.71%

* Approximation only. Some reports may have incomplete information.

Do you take Gliclazide and Aprepitant?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously